Response to Comments: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer

This document is a response-to-comments notice for MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer and does not itself define clinical coverage criteria, limitations, documentation requirements, or frequency limits. Coverage details and specific requirements are contained in MolDX LCD DL38649; the response notes the comment period (7/14/2022–8/27/2022), notice start (6/22/2023), and effective date (8/6/2023).

"This response-to-comments document does not specify clinical coverage indications; coverage decisions for prognostic and predictive molecular classifiers for bladder cancer are governed by MolDX LC..."

Sign up to see full coverage criteria, indications, and limitations.